Naloxazone irreversibly inhibits the high affinity binding of [125I]D-ala2-D-leu5-enkephalin.
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002478:Cells, Cultured; D004723:Endorphins / Q000378:metabolism*; D016308:Enkephalin, Leucine-2-Alanine; D004745:Enkephalins / Q000378:metabolism*; D066298:In Vitro Techniques; D007700:Kinetics; D008566:Membranes / Q000378:metabolism; D009020:Morphine / Q000378:metabolism; D009270:Naloxone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D051381:Rats; D011957:Receptors, Opioid / Q000378:metabolism*
D004723:Endorphins; D004745:Enkephalins; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D009270:Naloxone; D016308:Enkephalin, Leucine-2-Alanine; C024224:naloxazone; D009020:Morphine